Compare AKTX & NUTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKTX | NUTX |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | N/A | 944 |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5M | 655.4M |
| IPO Year | 2014 | 2009 |
| Metric | AKTX | NUTX |
|---|---|---|
| Price | $4.47 | $100.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $2.53 | ★ $252.50 |
| AVG Volume (30 Days) | ★ 329.1K | 165.9K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.93 |
| EPS | N/A | ★ 10.48 |
| Revenue | N/A | ★ $875,257,000.00 |
| Revenue This Year | N/A | $8.28 |
| Revenue Next Year | N/A | $1.96 |
| P/E Ratio | ★ N/A | $9.63 |
| Revenue Growth | N/A | ★ 82.36 |
| 52 Week Low | $0.12 | $66.09 |
| 52 Week High | $5.50 | $193.07 |
| Indicator | AKTX | NUTX |
|---|---|---|
| Relative Strength Index (RSI) | 85.60 | 50.66 |
| Support Level | $0.30 | $94.38 |
| Resistance Level | N/A | $108.47 |
| Average True Range (ATR) | 0.20 | 6.97 |
| MACD | 0.53 | 1.87 |
| Stochastic Oscillator | 80.85 | 88.24 |
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
Nutex Health Inc is a physician-led, healthcare services and operations company with various hospital facilities in the U.S. states (hospital division), and a primary care-centric, risk-bearing population health management division. The company has three segments: the hospital division, the PHM division, and the real estate division. The hospital division implements and operates health care models, including micro-hospitals, specialty hospitals and hospital outpatient departments (HOPDs). The population health management (PHM) division owns and operates provider networks such as independent physician associations (IPAs). The Real Estate Entities own the land and hospital buildings which are leased to its hospital entities. The majority of the revenue is derived from the Hospital division.